Lucid Diagnostics Inc. (NASDAQ:LUCD) Receives $10.50 Consensus Target Price from Brokerages

Lucid Diagnostics Inc. (NASDAQ:LUCDGet Rating) has received a consensus recommendation of “Buy” from the seven ratings firms that are covering the stock, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a buy rating. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $10.50.

A number of brokerages have recently weighed in on LUCD. Needham & Company LLC cut their target price on shares of Lucid Diagnostics from $13.00 to $7.00 and set a “buy” rating on the stock in a research note on Tuesday, March 29th. BTIG Research reaffirmed a “buy” rating and set a $5.00 target price on shares of Lucid Diagnostics in a research note on Friday, May 13th. Canaccord Genuity Group dropped their price objective on shares of Lucid Diagnostics from $12.00 to $8.00 in a research note on Thursday, May 12th. Ascendiant Capital Markets dropped their price objective on shares of Lucid Diagnostics to $13.00 in a research note on Thursday, June 9th. Finally, Canaccord Genuity Group dropped their price objective on shares of Lucid Diagnostics from $18.00 to $12.00 and set a “buy” rating on the stock in a research note on Tuesday, March 29th.

A number of institutional investors have recently modified their holdings of LUCD. KCL Capital L.P. purchased a new position in Lucid Diagnostics in the fourth quarter worth about $54,000. New York State Common Retirement Fund purchased a new position in Lucid Diagnostics in the fourth quarter worth about $74,000. Verition Fund Management LLC purchased a new position in Lucid Diagnostics in the first quarter worth about $122,000. State Street Corp raised its holdings in shares of Lucid Diagnostics by 24.4% during the first quarter. State Street Corp now owns 56,693 shares of the company’s stock valued at $190,000 after purchasing an additional 11,121 shares during the last quarter. Finally, Geneos Wealth Management Inc. purchased a new position in shares of Lucid Diagnostics during the first quarter valued at approximately $209,000. 8.84% of the stock is owned by institutional investors and hedge funds.

Shares of LUCD opened at $1.79 on Thursday. The firm’s 50-day moving average price is $2.08 and its 200-day moving average price is $3.35. Lucid Diagnostics has a 1-year low of $1.69 and a 1-year high of $13.52.

Lucid Diagnostics (NASDAQ:LUCDGet Rating) last announced its earnings results on Monday, March 28th. The company reported ($0.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.12). Research analysts expect that Lucid Diagnostics will post -1.42 EPS for the current year.

Lucid Diagnostics Company Profile (Get Rating)

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma.

See Also

Analyst Recommendations for Lucid Diagnostics (NASDAQ:LUCD)

Receive News & Ratings for Lucid Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lucid Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.